There’s A 14% Slump Ahead For AstraZenenca plc

Recovery might be coming for AstraZeneca plc (LON: AZN), but it’ll take a few more years.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

sdf

Since Pascal Soriot took the helm at AstraZeneca (LSE: AZN) (NYSE: AZN.US) in October 2012, investor confidence has been returning strongly. The share price is up 23% over the past 12 months, to 4,175p, and over three years it has picked up 35% against the FTSE’s 10% — and that’s impressive for a company that has seen earnings falling for two years in a row.

Earnings falling

AZNIn fact, earnings per share (EPS) slumped by 26% in 2013, in part due to the expiry of patents on some key drugs and increasing competition from generic alternatives.

With the shares on the rise again, you might think there’s a return to growth forecast. Well, no, there isn’t. The current consensus still suggests a further 14% fall in earnings for 2014, with a 2% slip to follow in 2015 — and that puts the shares on a forward P/E for 2015 of 16, which some will see as a bit high.

And we must remember that forecasts for rival GlaxoSmithKline, which faces the same industry problems, are looking a good bit better.

Past the bottom?

The trend of forecasts for AstraZeneca has been slipping, too. The same analysts who are now predicting 2014 EPS of 258p were touting 335p just a year ago, but at least it has firmed up a little in the past month, from a low of 255p.

Forecasts for 2015 have also started to reverse their downward movement, as updates from the company have started sounding a bit more bullish — as recently as last week, speaking of first-quarter results, Mr Soriot said “We are investing in our rapidly progressing pipeline and the key platforms that are the backbone of our strategy to return to growth“.

Against that optimism, however, there’s still a wide spread of opinions between individual analysts’ forecasts — though we’re awaiting adjustments after that first-quarter update.

ThumbDownOn the actual recommendation front, out of a sample of 32 commentators, five have posted Buy recommendations with 11 suggesting Sell. That puts a fairly large proportion of them in the remaining 15 who are sitting on the Hold fence — presumably waiting for concrete news before endorsing (or refuting) the company’s upbeat outlook.

Wait and see

What do I think? Well, GlaxoSmithKline looks the better investment to me right now, with better earnings and dividend forecasts, a lower P/E valuation, and that positive-looking Novartis deal in the bag.

On the whole, then, I’m with the “wait and see” crowd, and I think the short-term optimism might be overdone.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Alan does not own any shares in AstraZeneca or GlaxoSmithKline. The Motley Fool has recommended shares in GlaxoSmithKline.

More on Investing Articles

Finger clicking a button marked 'Buy' on a keyboard
Investing Articles

Analysts have upgraded this FTSE 100 stock to Buy. What should investors do?

Associated British Foods shares have been uninspiring for some time. But is it finally time to consider buying the FTSE…

Read more »

Man changing battery on electric bicycle
Investing Articles

Prediction: in 12 months the sizzling National Grid share price could turn £10,000 into…

It's been another solid year for the National Grid share price and the dividend yield is decent too. So why…

Read more »

Businessman using pen drawing line for increasing arrow from 2024 to 2025
Investing Articles

Up 185% in 3 years, why does the market love this FTSE 250 stock

Over the past three years, this stock has vastly outperformed the FTSE 250. Dr James Fox takes a closer look…

Read more »

A handsome mature bald bearded black man in a sunglasses and a fashionable blue or teal costume with a tie is standing in front of a wall made of striped wooden timbers and fastening a suit button
Investing Articles

Looking for growth, dividends, or value? These 3 ETFs could be smart ideas to consider

Exchange-traded funds (ETFs) provide a way for investors to spread risk without sacrificing the possibility of huge long-term returns.

Read more »

Happy couple showing relief at news
Investing Articles

Is the Rolls-Royce share price fast becoming a joke?

The FTSE 100 engineering titan has done brilliantly in recent years. But our writer wonders whether the Rolls-Royce share price…

Read more »

Middle-aged white male courier delivering boxes to young black lady
Investing Articles

Is there a ‘best age’ to start buying shares?

Christopher Ruane weighs some possible pros and cons of waiting to start buying shares for the first time, versus starting…

Read more »

piggy bank, searching with binoculars
Investing Articles

Is it time to look again at the FTSE 250’s worst performers?

Our writer considers the prospects for two of the worst-performing shares on the FTSE 250, with falls of at least…

Read more »

A handsome mature bald bearded black man in a sunglasses and a fashionable blue or teal costume with a tie is standing in front of a wall made of striped wooden timbers and fastening a suit button
Investing For Beginners

Down over 40% in the past year, I think investors should consider these value shares

Jon Smith points out two value shares that have fallen heavily over the past year but are starting to look…

Read more »